CSIRO announces COVID treatment project, new Chief Scientist
Australia’s national science agency, CSIRO, will spearhead a $1.7 million project to identify new treatments for COVID-19, including so-called ‘long COVID’. Scientists will develop a faster, smarter way of rapidly screening existing drugs and advancing those that can be used to treat COVID-19 and aim to have identified suitable TGA- or FDA-approved drug candidates to progress to phase 2–3 human clinical trials within a year.
Led by researchers at CSIRO’s Australian Centre for Disease Preparedness in Geelong, the project received $1 million in funding from the Australian Government’s Medical Research Future Fund (MRFF), with the remaining contributed by CSIRO. The initiative has academic collaborators from Barwon Health, Deakin University, Monash University, QIMR Berghofer Medical Research Institute, Swinburne University of Technology, The University of Melbourne and UNSW Sydney.
Project leader Dr SS Vasan, said in addition to vaccines, there is an urgent need for safe, effective and affordable COVID-19 treatments that specifically targeted the virus.
“A great strategy to find potential COVID-19 treatments is to repurpose drugs already approved for other diseases, but the current methods to do this are expensive, time-consuming and not fit-for-purpose,” Dr Vasan said.
“The MRFF funding will enable us to develop a multi-tissue drug screening tool, tailored for infections by SARS-CoV-2 and all its variants of concern, which could help fast-track drugs for phase 2–3 human clinical trials and minimise the need for animal trials.”
The scientists will use four types of clinically-relevant human tissues — lower respiratory tract, lung, neural and cardiac tissues — specifically selected based on how SARS-CoV-2 infects people. Project collaborator Professor Eugene Athan, Barwon Health’s Director of Infectious Diseases, said the lower respiratory tract and lung models are appropriate because they play a key role in severe infections.
“The neural and cardiac tissues are highly relevant because this disease is now known to cause neurologic disorders, heart dysfunction and damage in some patients,” Prof Athan said.
The scientists will use novel systems biology (a biomedical approach to understand the bigger picture) and machine learning methods to differentiate between healthy and diseased states of key human tissues, which will enable additional ways to determine if a drug is able to reliably restore a diseased tissue to a healthier state.
News of the project comes shortly after CSIRO announced the appointment of Professor Bronwyn Fox as its new Chief Scientist, close to 30 years after she began her career with CSIRO as a research assistant.
Prof Fox, CSIRO’s fourth female Chief Scientist, joins the agency from Swinburne University of Technology, where she is Deputy Vice-Chancellor (Research and Enterprise). As a materials and engineering scientist, she was the founding Director of Swinburne’s Manufacturing Futures Research Institute, with a mission to support the transition of Australia’s manufacturing sector to Industry 4.0.
She also is also currently Chair of the Australian Academy of Technology and Engineering (Victorian Division), a Fellow of the Academy of Technological Sciences and Engineering (ATSE), a Fellow of the Royal Australian Chemical Institute (RACI) and a Graduate of the Australian Institute of Company Directors (GAICD).
CSIRO Chief Executive Dr Larry Marshall said Prof Fox brings great depth of scientific experience to the role, describing her as “driven to deliver, brilliant but humble, leading by listening and a generous collaborator”.
“She has a long history of bringing together researchers from across multiple scientific domains and institutions, leveraging digital science, and helping industry to translate brilliant ideas into real-world solutions,” Dr Marshall said.
“Her sustained commitment to supporting the growth of the manufacturing industry in Australia strongly supports our purpose to deliver solutions from science that drive Australia’s economic recovery and resilience.”
Prof Fox said it was “wonderful to return to CSIRO as Chief Scientist after starting as a 22-year-old research assistant, and to be able to champion science research and capability, working with industry and fostering STEM careers”.
“The depth of scientific research at CSIRO and its committed people are a unique and special national treasure, and I look forward to taking up the role,” she concluded.
The NSW Health Commercialisation Training Program is a free training program for NSW-based...
The first episode of the video series is now live and focuses on palladium catalysed...
The 58th AACB Annual Scientific Conference will be held at Brisbane's Royal International...